

## REVISIÓN BIBLIOGRÁFICA

# Instituto de Estudios de Alcohol y Drogas

GONZÁLEZ DI GIOIA, A. B. y GARCÍA JIMÉNEZ, F. J.

*Universidad de Valladolid. Valladolid.*

### Introducción

Dada la actual controversia en relación al cannabis respecto a la naturaleza de sus efectos tóxicos, su capacidad o no de generar dependencia, sus posibles propiedades terapéuticas, la discusión sobre su estatus legal, etc., hemos realizado una búsqueda bibliográfica en la base de datos MEDLINE sobre el tema. A continuación se presenta una selección de los artículos publicados durante el período 2002-2003.

### Historia y cannabis

— KENDELL, R. Cannabis condemned: the proscription of Indian hemp *Addiction*. 2003;98,143-51.

### Neurobiología y cannabis

— WILSON RI, NICOLL RA. Endocannabinoid signaling in the brain. *Science* 2002;26;296:678-82.

— DAVIES SN, PERTWEE RG, RIEDEL G. Functions of cannabinoid receptors in the hippocampus. *Neuropharmacology* 2002; 42: 993-1007.

— MARTIN BR. Identification of the endogenous cannabinoid system through integrative. Pharmacological approaches. *J Pharmacol Exp Ther* 2002;301:790-6.

— ONAIVI ES, LEONARD CM, ISHIGURO H, ZHANG PW, LIN Z, AKINSHOLA BE, UHL GR. Endocannabinoids and cannabinoid receptor genetics. *Prog Neurobiol* 2002; 66:307-44.

### Toxicidad y cannabis

— FRIED PA. Conceptual issues in behavioral tera-

tology and their application in determining long-term sequelae of prenatal marihuana exposure. *J Child Psychol Psychiatry* 2002;43:81-102.

— DEGENHARDT L, HALL W. Cannabis and psychosis. *Curr Psychiatry Rep* 2002;4:191-6.

— DENNIS M, BABOR TF, ROEBUCK MC, DONALDSON J. Changing the focus: the case for recognizing and treating cannabis use disorders. *Addiction*. 2002;97 (Suppl 1):4-15.

— KAUL P, COUPEY SM. Clinical evaluation of substance abuse. *Pediatr Rev* 2002;23:85-94.

— SCHWARTZ RH. Marijuana: a decade and a half later, still a crude drug with underappreciated Toxicity. *Pediatrics* 2002;109:284-9.

— SMITH NT. A review of the published literature into cannabis withdrawal symptoms in human users. *Addiction* 2002;97:621-32.

### Uso terapéutico y cannabis

— BAGSHAW SM, HAGEN NA. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature. *J Palliat Care* 2002;18:111-22.

— BEAULIEU P, RICE AS. The pharmacology of cannabinoid derivatives: are there applications to treatment of pain? *Ann Fr Anesth Reanim* 2002;21: 493-508.

— CARTER GT, WEYD, P. Cannabis: old medicine with new promise for neurological disorders. *Curr Opin Investig Drugs* 2002;3:437-40.

— HALL W, MACPHEE D. Cannabis use and can-

cer. *Addiction* 2002;97:243-7.

bis use: psychiatric review and proposed guidelines. *J Forensic Sci* 2002;47:451-8.

### **Educación y cannabis**

— GRUBER AJ, POPE HG Jr. Marijuana use among adolescents. *Pediatr Clin North Am* 2002;49:389-413.

— GROSSMAN M, CHALOUPKA FJ, SHIM K. Illegal drug use and public policy. One can support the war on drugs' goal of reducing consumption without supporting the war itself. *Health Aff* 2002;21:134-45.

### **Conducción y cannabis**

— O'KANE CJ, TUTT DC, BAUER LA. Cannabis and driving: a new perspective. *Emerg Med* 2002;14:296-303.

### **Debate sobre cannabis**

— WODAK A, REINARMAN C, COHEN PD, DRUMMOND C. Cannabis control: costs outweigh the benefits. *For. BMJ* 2002, 12;324:105-6.

— DRUMMOND C. Cannabis control: costs outweigh the benefits. *Against. BMJ* 2002, 12;324:107-8.

### **Aspectos legales y cannabis**

— NIVEAU G. Criminal responsibility and canna-

### **Enlaces de interés**

<http://www.marijuana-info.org/>

<http://www.nida.nih.gov/Infofax/Marijuana-Sp.html>